Improved AAV Gene Therapies: Precision, Targeting, and Common Diseases


Adeno-associated viruses (AAVs) have been the preferred vectors for gene therapies due to their safety and efficacy. At the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, researchers will discuss the latest advancements in AAV technology that are enhancing precision and expanding the scope of treatable diseases.

Improved AAV vectors are enabling more targeted gene delivery, reducing off-target effects and increasing the efficiency of gene transfer. Additionally, novel AAV serotypes and engineered capsids are being developed to overcome pre-existing immunity and enable repeated dosing. These advancements are paving the way for AAV-based gene therapies to tackle more common diseases affecting larger patient populations.

The ASGCT meeting will showcase cutting-edge research on AAV optimization, as well as other exciting developments in the field of cell and gene therapy. As AAV technology continues to evolve, it holds great promise for revolutionizing the treatment of genetic disorders and beyond.